Modern medicine keeps on advancing each day. One medicine that has been very effective in carrying out a number of procedures has been Rapamycin or Sirolimus. Among the many uses of this drug include the treatment of uncommon lung diseases, acts as a coat for coronary stents, and lastly helps in preventing organ transplant rejection.Rapamycin, however, is not a new medicine in the world. This drug was discovered in 1972; however, it was majorly used as an anti-fungal agent. With the advancement in research operations, this drug was discovered to have a lot of benefits including being a great antiproliferative and immunosuppressive. It is as a result of these features that physicians and researchers such as Mikhail Blagosklonny have endorsed it for the treatment of cancer. The following are some of the benefits of Rapamycin according to Mikhail Blagosklonny.
Helps in Treating Patients With Hemolytic-Uremic Syndrome
Hemolytic-uremic syndrome is a condition caused due to the combination of kidney failure, low platelet count, and anemia. This condition is fatal as it may results in renal failure hence leading a patient to be dependent on dialysis all of his or her lifetime. The only preventative cure for this condition is always through kidney transplants. Unlike with calcineurin inhibitors, Rapamycin has a high probability of helping you succeed in the transplant operations as it lowers the toxicity levels in your kidneys.
Treatment of Cancer
Mikhail Blagosklonny is a lead researcher when it comes to cancer. According to his research, Rapamycin’s antiproliferative properties are what helps this drug to be effective in the treatment of cancer. This drug works in two ways; first, it helps boosts our body’s immunity response. Secondly, its effects help to suppress the growth of the cancer tumor thus helping reduce the risks of cancer in patients and more so those undergoing organ transplants.
About Mikhail Blagosklonny and his Plan for Oncology
Mikhail Blagosklonny is one of the most respected scientists in the field of oncology. With cancer being one of the world’s biggest medical menaces, Mikhail Blagosklonny, through his researches, is committed to helping patients and their family ease on the cancer burden. Currently, Dr. Mikhail Blagosklonny is a professor, editor, and researcher at New York’s Rosewell Park Cancer Institute in Buffalo where he also gets to play his editorial duties at OncorTarget an online oncology publication.Dr. Mikhail Blagosklonny has to his name a number of published research works. His specialty is in the area of cancer and the effects of aging. Mikhail Blagosklonny is seeking to establish how these two areas can be merged to help come up with an effective cure for cancer. So far the progress is good if the OncorTarget publication is anything to go by. This publication has been able to attract many online readers thus creating a rich source of affordable information to both researchers and the general public leading to improved quality of life.Going into the future, Mikhail Blagosklonny has more plans not only for himself but also for his publication. He seeks to improve the quality of life and make life more bearable for cancer patients and their families by creating a cure and making the cancer information available.